Exploration on clinical characteristics of adverse reactions in postoperative chemotherapy of breast cancer

doi:10.3877/cma.j.issn.1674-0793.2016.03.011

Abstract

Abstract:

Objective

To analyze the characteristics of adverse reactions in postoperative chemotherapy of breast cancer.

Methods

Sixty-eight patients of invasive breast cancer treated in Breast Disease Treatment Center of Chongqing Institute of Cancer from January 2011 to January 2014 were randomly divided into observation group and control group. The observation group were treated with AC→T regimen, and the control group with TAC regimen. Immune function, blood and cytokine level changes 1 day before and 7 days after chemotherapy were compared. After chemotherapy, adverse reactions and clinical characteristics of the two groups were observed.

Results

After chemotherapy, CD4⁺, CD8⁺, CD4⁺/CD8⁺ of the observation group were significantly higher than control group [(43.22 ± 2.76)% vs (37.32±1.78)%, (42.45±4.32)% vs (34.22±3.26)%, (1.96±0.35) vs (1.43±0.42), all P<0.000 1]. Immunoglobulin IgA, IgG, IgM levels of observation group were significantly lower than control group respectively [(1.25±0.11) g/L vs (2.01±0.26) g/L、(8.21±1.22) g/L vs (11.34±2.33) g/L, (1.24±0.21) g/L vs (1.76±0.34) g/L, all P<0.000 1]. PLT, WBC, IL-4, IL-10 levels of observation group were significantly higher than control group [(175±24)×10⁹/L vs (159±25)×10⁹/L、(8.43±2.42)×10⁹/L vs (7.11±1.78)×10⁹/L、(46.32±4.22) U/ml vs (34.21±3.87) U/ml、(34.21±4.21) U/ml vs (25.45±3.87) U/ml, P=0.009、0.013、<0.000 1、<0.000 1]. The adverse reaction rates of fever with neutropenia and reduction were 44.12% and 26.47%, lower than the control group (χ²=8.967, 10.019, P=0.003, 0.002).

Conclusion

The cancer patients taking chemotherapy have different adverse reactions, most of which are below degree Ⅲ, well tolerated, and can be improved after treatment.

Key words: Breast neoplasmas, Drug therapy, combination

Ling Liu, Xin Cao. Exploration on clinical characteristics of adverse reactions in postoperative chemotherapy of breast cancer[J]. Chinese Archives of General Surgery(Electronic Edition), 2016, 10(03): 209-212.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2016.03.011

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2016/V10/I03/209

Figures/Tables 3

References 15

1	艾中平,周建荣.乳腺癌化疗相关症状随疗程的变化趋势[J].中国老年学杂志, 2013, 33(10): 2346-2348.
2	张晓辉,孙强,周易冬,等.早期乳腺癌患者AX方案辅助化疗的不良反应及生活质量观察[J].中国普通外科杂志, 2012, 21(5): 499-502.
3	张晓清,刘鹏熙,任黎萍,等. TAC与FAC方案在乳腺癌新辅助化疗中的疗效比较[J].实用医学杂志, 2011, 27(1): 38-40.
4	陈建林,季丽萍.乳腺癌术后化疗常见不良反应的护理干预[J].江苏医药, 2015, 22(5): 616-617.
5	邹菊,王松,梁庆模.乳腺癌新辅助化疗疗效的评价方法[J/CD].中华普通外科学文献:电子版, 2012, 6(1): 71-74.
6	吴乔,张国强,王姗.小于全乳切除联合化疗治疗乳腺癌的研究[J].中国妇幼保健, 2014, 34(20): 3341-3343.
7	Vulsteke C,Pfeil AM,Maggen C, et al. Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients[J]. Breast Cancer Res Treat, 2015, 152(1): 67-76.
8	韩颖,李青,徐兵河,等.老年乳腺癌患者应用非蒽环类辅助化疗方案的安全性及耐受性临床研究[J].中国癌症杂志, 2014, 55(5): 367-373.
9	张彦,李曼,赵璐,等.乳腺癌不同剂量表柔比星联合辅助化疗的疗效分析[J].中华肿瘤防治杂志, 2014, 15(15): 1168-1173.
10	张凤春,徐海燕,徐光如,等.胸苷酸合成酶基因多态性与不同种族乳腺癌FEC方案化疗不良反应相关性研究[J].上海交通大学学报(医学版), 2014, 41(6): 850-854.
11	盛树海,郑进,刘广寅,等.多西紫杉醇和表阿霉素及环磷酰胺联合化疗与序贯化疗近期不良反应的比较[J].广东医学, 2013, 21(11): 1773-1775.
12	Rebegea L,Firescu D,Dumitru M, et al. The incidence and risk factors for occurrence of arm lymph edema after treatment of breast cancer[J]. Chirurgia (Bucur), 2015, 10(1): 7-33.
13	陈江华,赵建华,唐金海,等.环磷酰胺代谢酶基因多态性与乳腺癌化疗反应相关性的探讨[J].中华肿瘤防治杂志, 2012, 32(10): 726-730.
14	徐玉瑞,巢琳,陈力平. TC与CEF方案作为早期乳腺癌术后辅助化疗方案的临床比较[J].广东医学, 2011, 32(21): 2805-2808.
15	韩冬梅,陆浩杨.乳腺癌术后化疗不良反应的护理[J].山东医药, 2011, 18(50): 21.

组别	例数	年龄（岁， ± s）	绝经情况（例）		病理类型（例）				TNM分期（例）
组别	例数	年龄（岁， ± s）	绝经前	绝经后	浸润性导管癌	浸润性小叶癌	黏液癌	髓样癌	ⅡA期	ⅡB期	ⅢA期	ⅢB期
观察组	34	46.22±4.21	15	19	21	7	3	3	2	5	14	13
对照组	34	46.18±4.17	14	20	18	9	2	5	3	7	12	12
统计值	?	t=0.039	χ²=0.060		?	χ²=1.181		?	?	χ²=0.727		?
P值	?	0.969	0.806		?	0.758		?	?	0.867		?

组别	例数	年龄（岁， ± s）	绝经情况（例）		病理类型（例）				TNM分期（例）
组别	例数	年龄（岁， ± s）	绝经前	绝经后	浸润性导管癌	浸润性小叶癌	黏液癌	髓样癌	ⅡA期	ⅡB期	ⅢA期	ⅢB期
观察组	34	46.22±4.21	15	19	21	7	3	3	2	5	14	13
对照组	34	46.18±4.17	14	20	18	9	2	5	3	7	12	12
统计值	?	t=0.039	χ²=0.060		?	χ²=1.181		?	?	χ²=0.727		?
P值	?	0.969	0.806		?	0.758		?	?	0.867		?

组别	例数	CD4⁺(%)		CD8⁺(%)		CD4⁺/CD₈+		IgA(g/L)		IgG(g/L)
组别	例数	化疗前	化疗后	化疗前	化疗后	化疗前	化疗后	化疗前	化疗后	化疗前	化疗后
观察组	34	32.07±1.76	43.22±2.76	27.46±1.43	42.45±4.32	1.07±0.15	1.96±0.35	2.54±0.42	1.25±0.11	14.21±3.22	8.21±1.22
对照组	34	32.11±1.78	37.32±2.35	27.65±1.46	34.22±3.26	1.08±0.16	1.43±0.42	2.57±0.32	2.01±0.26	14.25±3.21	11.34±2.33
t值	?	0.093	9.491	0.542	8.867	0.266	5.653	0.331	15.697	0.051	6.939
P值	?	0.926	<0.000 1	0.589	<0.000 1	0.791	<0.000 1	0.742	<0.000 1	0.959	<0.000 1
组别	例数	IgM(g/L)		PLT(×10⁹/L)		WBC(×10⁹/L)		IL-4(U/ml)		IL-10(U/ml)
组别	例数	化疗前	化疗后	化疗前	化疗后	化疗前	化疗后	化疗前	化疗后	化疗前	化疗后
观察组	34	2.35±0.52	1.24±0.21	146±21	175±24	5.34±1.03	8.43±2.42	21.45±3.53	46.32±4.22	18.02±3.52	34.21±4.21
对照组	34	2.41±0.54	1.76±0.34	147±23	159±25	5.37±1.07	7.11±1.78	21.36±3.55	34.21±3.87	18.08±3.54	25.45±3.87
t值	?	0.467	7.587	0.187	2.692	0.118	2.562	0.105	12.332	0.070	8.932
P值	?	0.642	<0.000 1	0.852 1	0.009	0.906 6	0.013	0.917	<0.000 1	0.944	<0.000 1

组别	例数	CD4⁺(%)		CD8⁺(%)		CD4⁺/CD₈+		IgA(g/L)		IgG(g/L)
组别	例数	化疗前	化疗后	化疗前	化疗后	化疗前	化疗后	化疗前	化疗后	化疗前	化疗后
观察组	34	32.07±1.76	43.22±2.76	27.46±1.43	42.45±4.32	1.07±0.15	1.96±0.35	2.54±0.42	1.25±0.11	14.21±3.22	8.21±1.22
对照组	34	32.11±1.78	37.32±2.35	27.65±1.46	34.22±3.26	1.08±0.16	1.43±0.42	2.57±0.32	2.01±0.26	14.25±3.21	11.34±2.33
t值	?	0.093	9.491	0.542	8.867	0.266	5.653	0.331	15.697	0.051	6.939
P值	?	0.926	<0.000 1	0.589	<0.000 1	0.791	<0.000 1	0.742	<0.000 1	0.959	<0.000 1
组别	例数	IgM(g/L)		PLT(×10⁹/L)		WBC(×10⁹/L)		IL-4(U/ml)		IL-10(U/ml)
组别	例数	化疗前	化疗后	化疗前	化疗后	化疗前	化疗后	化疗前	化疗后	化疗前	化疗后
观察组	34	2.35±0.52	1.24±0.21	146±21	175±24	5.34±1.03	8.43±2.42	21.45±3.53	46.32±4.22	18.02±3.52	34.21±4.21
对照组	34	2.41±0.54	1.76±0.34	147±23	159±25	5.37±1.07	7.11±1.78	21.36±3.55	34.21±3.87	18.08±3.54	25.45±3.87
t值	?	0.467	7.587	0.187	2.692	0.118	2.562	0.105	12.332	0.070	8.932
P值	?	0.642	<0.000 1	0.852 1	0.009	0.906 6	0.013	0.917	<0.000 1	0.944	<0.000 1

组别	例数	中性粒细胞减少	减少性的中性粒细胞发热	水钠潴留	外周神经毒性	皮肤指甲改变	过敏
观察组	34	15(44.12)	9(26.47)	0(0.00)	1(2.94)	1(2.94)	0(0.00)
对照组	34	27(79.41)	22(64.71)	1(2.94)	1(2.94)	2(5.88)	1(2.94)
χ²值	?	8.967	10.019	1.015	0.000	0.349	1.015
P值	?	0.003	0.002	0.314	1.000	0.555	0.314

Please choose a citation manager

Content to export